# CJC-1295 no DAC — dosage, half-life & reference guide Source: https://pepvault.app/peptides/cjc-1295-no-dac Last updated: 2026-09-26 [Library](https://pepvault.app/peptides) [Growth hormone](https://pepvault.app/peptides#growth-hormone) reviewed September 2026 # CJC-1295 no DAC Dosage, half-life & reference guide Also known as Modified GRF 1-29 · Mod GRF 1-29 · CJC-1295 without DAC The shorter-acting version of CJC-1295, meant to give sharp, pulse-like GH release. Almost always stacked with Ipamorelin: together they release more GH than either alone, a synergy well established for the two drug classes. - **Studied range:** 100–200 mcg - **How often:** 2–3× daily - **Half-life:** ~30 min - **Evidence:** Moderate - **Route:** SubQ injection Studied in research — not a recommendation. [CJC-1295 no DAC dose guide](https://pepvault.app/lab/dosage/cjc-1295-no-dac) ## How it works. GHRH analogue without the DAC modification. Its half-life in people hasn't been measured (native GHRH lasts minutes), and the short action gives pulse-like GH release. Usually stacked with Ipamorelin to mimic natural GH secretion patterns. **Commonly reported:** A flush or head rush within minutes of injecting, deeper sleep and vivid dreams early on, and mild water retention over the weeks. The no-DAC form itself has no published human studies. ### Half-life & active level The half-life of CJC-1295 no DAC is ~30 min (community estimate; not measured in people: sermorelin, the unmodified 1-29 chain, lasts 11–12 minutes). Here's how a typical CJC-1295 no DAC schedule plays out over 48 hours (one-compartment estimate). An estimate from the half-life above, not a measurement. See your own curve build live in [the half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator). ## Where CJC-1295 no DAC works. - ### Brain, nerves & sleep **Reported by users.** Commonly reported first: deeper sleep and vivid dreams. - ### Appetite & metabolism **Reported by users.** More lean mass and modest fat loss, with sleep strong and consistent. - ### Muscle **Reported by users.** Commonly reported in weeks 4 to 8: visible body-composition changes, more lean mass. An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there. ## Week by week. What to expect in the first 8 weeks - **Onset:** 1–2 weeks - **Peak effect:** 8–12 weeks - **Duration:** 8–12 weeks 1. Day 1–14 Community ### Sleep usually moves first Commonly reported first: deeper sleep and vivid dreams. The short action is the point of the no-DAC form: sharp GH pulses rather than a raised baseline. The science Mechanism: a GHRH-receptor agonist that amplifies GH release by activating GHRH receptors on pituitary somatotrophs. Countering somatostatin is what GHRPs like ipamorelin add, which is why the two are paired (Ghigo 1997). The short action avoids continuous receptor occupancy. Sources - Ghigo et al. (1997) Updated Sep 2026 2. Day 14–28 Community ### Recovery is quicker, skin looks better Commonly reported: faster recovery, and skin that looks tighter and better hydrated. IGF-1 rises only modestly with the no-DAC form, though that hasn't been measured in people. The science Unlike CJC-1295 WITH DAC (5.8–8.1-day half-life, IGF-1 up 1.5–3x for 9–11 days; Teichman 2006), the no-DAC version is meant to keep IGF-1 milder, but its effect hasn't been measured in humans. In a human study, pulsed GH raised fat breakdown more than continuous GH, which raised IGF-1 more (Surya 2009). Sources - Teichman et al. (2006) - Surya et al. (2009) Updated Sep 2026 3. Day 28–56 Community ### Body composition starts shifting Commonly reported in weeks 4 to 8: visible body-composition changes, more lean mass and modest fat loss, with sleep strong and consistent. The science No controlled human body-composition trial exists for CJC no DAC; the expectation rests on GHRH physiology (IGF-1, fat breakdown, lean mass) and user reports. Updated Sep 2026 4. Day 56–84 Community ### Cycle endpoint Community convention is 8–12 weeks on, 4–8 off — but no RCT has defined a real endpoint here. GHRH analogs amplify your own pulses rather than overriding them, so the continuous-use case is defensible if labs stay stable. Holding, maintenance, or a break are all within reasonable practice; many find gains hold through an off-cycle if sleep and training don't slide. The science CJC-1295 isn't FDA-approved, and FDA has flagged it for possible immune reactions and serious adverse events. Continuous dosing hasn't been studied for long-term safety; the 8–12 week on / 4–8 week off convention is community-driven conservative practice, not trial-guided. Updated Sep 2026 5. Any day Clinical ### What CJC-1295 no DAC is built on The no-DAC version is the short-acting counterpart of the DAC version, meant for pulse-like dosing. GHRH-plus-GHRP synergy has been shown in human GH studies since 1990, which is why the ipamorelin stack is the go-to; the no-DAC form itself has no published human studies. The science DAC version (Teichman 2006, J Clin Endocrinol Metab): 2–10x GH increase, 1.5–3x IGF-1 sustained for 9–11 days per injection. The no-DAC version (Mod GRF 1-29) is chosen by users who want shorter, pulse-like dosing. No trial of the specific Ipa+CJC no-DAC combo exists, but the GHRH+GHRP synergy is well established (Bowers 1990). Sources - Teichman et al. (2006) - Bowers et al. (1990) Updated Sep 2026 6. With Ipamorelin Community ### The core GH stack The foundational GH stack: CJC-1295 amplifies each GH pulse and ipamorelin triggers it without raising cortisol (in animal studies), so together they give a larger GH response than either alone. Commonly reported: deeper sleep and better recovery than either alone. The science Mechanism: a GHRH analog (CJC) plus a GHRP (Ipa) releases more GH than the sum of each alone, a synergy well established for the two drug classes. CJC-1295 with DAC raised GH 2- to 10-fold (Teichman 2006); the no-DAC form hasn't been measured in humans. Users commonly co-inject them from one syringe; no compatibility study has been published. Sources - Teichman et al. (2006) - Ishida et al. (2020) Updated Sep 2026 7. Any day Clinical ### Where CJC-1295 sits in the GH family Think of the GH-secretagogue family in two halves: the GHRH side that lifts the baseline and the GHRP side that fires the pulse. CJC-1295 (no DAC) is a short-acting GHRH analog (its human half-life hasn't been measured), meant to amplify your own pulse — which is why it's paired with a GHRP like Ipamorelin instead of run alone. Sermorelin is the shorter-lived, gentler cousin; the with-DAC version is the long-acting one, which raises baseline GH while pulses continue. The science CJC-1295 no DAC (Mod GRF 1-29) is a short-acting GHRH-receptor agonist that preserves pulsatile GH architecture; the with-DAC version binds albumin for a 6–8 day half-life and raises baseline GH while pulses continue (Ionescu 2006). Compared with Sermorelin (native GHRH 1-29, ~11–12 min half-life, more degradation-prone), the four substitutions in Mod GRF 1-29 confer enzymatic resistance and a cleaner pulse. Positioning only — drawn from established pharmacology, no new claims. Sources - Teichman et al. (2006) - Ionescu & Frohman (2006) Updated Sep 2026 Day 1 is the day you start it. GHRH pharmacology is well understood, but the no-DAC form has no published human studies; timelines are community-reported. Moderate evidence ## Mixing and a typical run. Example numbers ### Reconstitution example Reconstitute a 5 mg vial of CJC-1295 no DAC with 2 mL of bacteriostatic water and a 150 mcg dose is 6 units on a U-100 syringe, about 33 doses per vial. - **Vial:** 5 mg - **Water:** 2 mL - **Amount:** 150 mcg Draw to **6 units** 0.3 mL insulin syringe · 30 units [Mix it in the Reconstitution Lab](https://pepvault.app/lab) [Open the calculator](https://pepvault.app/tools/reconstitution-calculator) ### Run notes - **Cycle:** 8–12 weeks typical. Usually stacked with Ipamorelin; cycle both together. Community practice — opinions vary. Not a clinical recommendation. - **Timing:** Inject fasted or 2h post-meal. Stack with Ipamorelin in same syringe. - **Route:** SubQ injection - **Stacks:** Ipamorelin, Sermorelin ## Safety. ### Common side effects - Water retention - Headache - Flushing - Injection site pain #### Interactions No formal human interaction studies exist. The key mechanism-based consideration is glucose/insulin sensitivity from sustained GH/IGF-1 elevation — relevant alongside insulin or antidiabetic agents and worth clinician-guided monitoring. Almost always combined with a ghrelin agonist (ipamorelin) for synergistic GH release; this is well-described in practice but lacks formal combination safety trials. No documented interaction with SSRIs, anticoagulants, or thyroid meds; raise all medications with your clinician. ### Safety notes CJC-1295 without DAC (mod GRF 1-29) is a short-acting GHRH analog with no published human safety study of its own; the phase 1 safety data (relatively well tolerated at 30–60 mcg/kg) are for the long-acting DAC form. FDA says it has identified serious adverse events with CJC-1295, including increased heart rate and systemic vasodilatory reactions, and flags a possible risk of immune reactions. Commonly reported effects are transient water retention, flushing, headache, tingling or numbness in the hands, and possible effects on glucose/insulin sensitivity from GH/IGF-1 elevation; as a short-acting form, these tend to be shorter-lived. Long-term human safety data are lacking. Discuss IGF-1 and glucose monitoring with your clinician. ## Goes with. - [Ipamorelin](https://pepvault.app/peptides/ipamorelin) - [Sermorelin](https://pepvault.app/peptides/sermorelin) - ### In the GH Pulse + Repair stack Body composition, GH optimization & recovery With [Ipamorelin](https://pepvault.app/peptides/ipamorelin) and [BPC-157](https://pepvault.app/peptides/bpc-157) - ### In the CJC-1295 + Ipamorelin stack Classic GH pulse stack — CJC-1295 no DAC + Ipamorelin With [Ipamorelin](https://pepvault.app/peptides/ipamorelin) ## Compared with. - [CJC-1295 no DAC vs Ipamorelin](https://pepvault.app/peptides/compare/cjc-1295-no-dac-vs-ipamorelin) - [CJC-1295 with DAC vs CJC-1295 no DAC](https://pepvault.app/peptides/compare/cjc-1295-with-dac-vs-cjc-1295-no-dac) ## Questions people ask. ### What is CJC-1295 no DAC? The shorter-acting version of CJC-1295, meant to give sharp, pulse-like GH release. Almost always stacked with Ipamorelin: together they release more GH than either alone, a synergy well established for the two drug classes. ### How is CJC-1295 no DAC dosed in research? The research range for CJC-1295 no DAC is 100–200 mcg, 2–3x daily. Studied in research — not a recommendation. ### How long does CJC-1295 no DAC last? The half-life of CJC-1295 no DAC is ~30 min (community estimate; not measured in people: sermorelin, the unmodified 1-29 chain, lasts 11–12 minutes). ### What do people report on CJC-1295 no DAC? Commonly reported on CJC-1295 no DAC: A flush or head rush within minutes of injecting, deeper sleep and vivid dreams early on, and mild water retention over the weeks. The no-DAC form itself has no published human studies. ### Is CJC-1295 no DAC safe? The research basis for CJC-1295 no DAC is moderate: animal studies + some human data. Common side effects in the library: water retention, headache, flushing and injection site pain. ### What does CJC-1295 no DAC stack with? Common stacks for CJC-1295 no DAC: Ipamorelin and Sermorelin. Curated stacks with CJC-1295 no DAC: GH Pulse + Repair and CJC-1295 + Ipamorelin. ## Research. The literature ### Search the latest research [PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295%20no%20DAC) [Google Scholar](https://scholar.google.com/scholar?q=CJC-1295%20no%20DAC) Guide ### [What to take alongside each peptide](https://pepvault.app/guides/what-to-take-with-peptides) Read the guide ## Reference. - **Cadence:** 2–3× daily 2–3x daily - **Half-life:** ~30 min ~30 min (community estimate; not measured in people: sermorelin, the unmodified 1-29 chain, lasts 11–12 minutes) - **Research basis:** Moderate Animal studies + some human data ## More growth hormone peptides - [Tesamorelin 1–2 mg](https://pepvault.app/peptides/tesamorelin) - [GHRP-2 100–300 mcg](https://pepvault.app/peptides/ghrp-2) - [GHRP-6 100–300 mcg](https://pepvault.app/peptides/ghrp-6) - [Hexarelin 100–200 mcg](https://pepvault.app/peptides/hexarelin) - [MK-677 10–25 mg](https://pepvault.app/peptides/mk-677) - [Fragment 176-191 250–500 mcg](https://pepvault.app/peptides/fragment-176-191) ## Free tools - [CJC-1295 no DAC dose guide](https://pepvault.app/lab/dosage/cjc-1295-no-dac) - [Reconstitution Lab (3D)](https://pepvault.app/lab) - [Injection guide (3D)](https://pepvault.app/lab/injection) - [Peptide Sky (3D)](https://pepvault.app/lab/sky) - [Peptide tier list](https://pepvault.app/lab/tiers) - [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator) - [Half-life & active level](https://pepvault.app/tools/peptide-half-life-calculator) PepVault for iPhone ## Track CJC-1295 no DAC in PepVault Log every dose, keep your vial and the doses left in it and watch its estimated active level. 7 days free on the yearly plan for new subscribers. [Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=peptides-cta&mt=8) [Open the calculator](https://pepvault.app/tools/reconstitution-calculator) [How the vial count works](https://pepvault.app/peptide-vial-tracker-app) [Explore the live demo](https://pepvault.app/login) Reviewed September 2026 [How we check the library](https://pepvault.app/about#library) PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them. PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it. © 2026 PepVault